3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
CNS
5
Sarcoma
3
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Brain Neoplasms
2
Recurrence
1
Glioma
1
Interventions
Radiotherapy
216
Cyclophosphamide
211
Doxorubicin
207
Temozolomide
181
Ifosfamide
121
Filgrastim
111
Etoposide
101
Imatinib Mesylate
99
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
79
Irinotecan
79
pembrolizumab
75
Radiation
67
Carboplatin
65
pazopanib
60
Methotrexate
60
Nivolumab
58
Cisplatin
58
fludarabine phosphate
56
Peripheral Blood Stem Cell Transplantation
56
Specimen Handling
53
Docetaxel
50
Busulfan
48
Trabectedin
47
Biopsy
47
Melphalan
46
Surgical Procedures, Operative
45
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
rindopepimut
×
Sarcoma
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled
NCT00626015
2016-01-21
ZAP IT
Duke University
Phase 1
Completed
16 enrolled